StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
VHL.AX$0.01+10.00%
Fair $0.01+0.0%

VHL.AX

Vitasora Health Limited

Healthcare / Health Information ServicesASX

$0.01

+0.00 (+10.00%)

Fairly Valued+0.0%Fair Value $0.01Fund rank 30/100 · Data gapFallback financials|
SA 23/D
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-6.6M · quality 62.0/100

Data gap 30/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

23/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -68.9%, below the 5% threshold
Thesis & Journal · VHL.AXLocal privado en este navegador · Vitasora Health Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$21M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-68.9%

↓

Gross Margin

99.0%

↑

Debt/Equity

0.00

↓
52-Week Range$0
$0$0

TradingView lightweight chart

VHL.AX price, volumen y niveles de valoración

Último $0.011Periodo -100.0%
Fair value: $0.011

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+130.2%

FCF CAGR

—

FCF margin

-296.3%

FCF / Net income

0.91x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $3.1M · net income $-10.1M · FCF $-9.2M

2022-FY → 2025-FY

Gross margin

99.0%+101.2% pts

Operating margin

-346.3%+2441.7% pts

Net margin

-326.6%+2284.6% pts

FCF margin

-296.3%+3046.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$3.1M$3.1M$456914.00$70533.00$253688.00
Net Income$-10.1M$-10.1M$-7.4M$-5.8M$-6.6M
EBITDA$-10.7M$-10.7M$-7.3M$-5.7M$-7.0M
EPS-0.01-0.01-0.01-0.01-0.01
Gross Margin99.0%99.0%100.0%7.0%-2.2%
Operating Margin-346.3%-346.3%-1673.4%-9005.5%-2788.0%
Net Margin-326.6%-326.6%-1627.5%-8188.1%-2611.2%
Balance Sheet
Debt/Equity0.000.000.500.180.02
Current Ratio2.952.95———
Cash Flow
Free Cash Flow$-9.2M$-9.2M$-6.6M$-4.5M$-8.5M
Returns
ROE-68.9%-68.9%-286.8%-698.4%-220.2%
Valuation
P/B1.051.0510.2032.1812.35
Growth & Yield
Revenue Growth577.1%577.1%547.8%-72.2%—
EPS Growth1.4%1.4%-1.4%20.9%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -72.5%

Total return

-72.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.01 → -0.01

Residual

-72.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-72.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.